Mayo Clinic receives patent for GeneSight

Share this article:

 

The Mayo Clinic has received a patent for a new medication selection procedure. GeneSight uses a test to prioritize the selection of medications for patients with depression, chronic pain and other psychiatric disorders.

 

GeneSight tests for genetic variants that affect a patient's response to psychotropic and analgesic medications, allowing clinicians to make evidence-based decisions about drug selection.

 

The company said the tool should help skilled nursing facilities reduce their use of antipsychotics.

Share this article:
close

Next Article in Products